24/7 Wall St. » PPHM

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

247wallst — Wed, 27 May 2009 18:34:32 +0000

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend. This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies: Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

The full presentation can be seen at BioHealthInvestor.com.

JON C. OGG
May 27, 2009

Posted in Biotech, Drug companies, FDA, Medical, Pharmaceuticals Tagged: ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CELG, CGRB, CLDX, CTIC, EXEL, GHDX, GSK, IMGN, LLY, MDVN, MEDX, MITI, OGXI, OSIP, PFE, PPHM, ROSG, SNTA, TRBN, ZGEN, ZIOP

Previewing 2009 ASCO Abstracts (ABII, ALTH, ARQL, CLDX, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, OGXI, OSIP, PPHM, PFE, SNTA, ZIOP)

247wallst — Thu, 14 May 2009 21:56:52 +0000

We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009. At BioHealthInvestor.com we compiled a brief summary for companies such as Abraxis BioScience, Inc. (NASDAQ:ABII), Allos Therapeutics, Inc. (NASDAQ: ALTH), Arqule Inc. (NASDAQ: ARQL), Celldex Therapeutics (NASDAQ: CLDX), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Synta Pharmaceuticals (NASDAQ: SNTA), and ZIOPHARM Oncology (NASDAQ: ZIOP).

You can see that full pre-report here at BiohealthInvestor.com. As always be advised that there may be new sets of data released between now and the actual meeting from May 29 to June 2, 2009 in Orlando, Florida.

Posted in Biotech, Drug companies, Medical, Pharmaceuticals Tagged: ABII, ALTH, ARQL, CGRB, CLDX, CTIC, EXEL, GHDX, GSK, IMGN, LLY, MDVN, MEDX, OGXI, OSIP, PFE, PPHM, SNTA, ZIOP

Biotech Busine$$ Daily (ALKS, CADX, CVTX, MNKD, GNBT, PPHM)

247wallst — Mon, 14 Apr 2008 12:16:42 +0000

Alkermes (NASDAQ: ALKS) and Johnson & Johnson Pharmaceutical Research and Developed today submitted paperwork seeking approval of their partnership drug, RISPERDAL CONSTA, to be allowed for treatment of bipolar disorder chronic relapse. The drug was already approved for treatment of schizophrenia in 2003. Shares of Alkermes are down to by $0.17 to $10.94 in mid-day trading on a 52-week range of $10.32 to $18.78.

Cadence Pharmaceuticals Inc. (NASDAQ: CADX) up over 8% today on no new developments to $6.74 off a 52-week range of $4.84 to $20.67. Cadence Pharmaceuticals is a development stage biopharmaceutical company with two products in Phase III testing, Acetavance and Omigard.

CV Therapeutics (NASDAQ: CVTX) down today despite FDA approval for its coronary artery treatment, Lexiscan, granted last Friday. The drug is injected into patients during heart tests that cannot exercise to increase blood flow in their arteries. The drug will be marketed by OTC company Astellas Pharma US Inc. and will pay CV Therapeutics $12 million now that drug has been approved. CV Therapeutics is down over 5% to $7.57 on a 52-week range of $5.41 to $13.74.

Mannkind Corp. (NASDSQ: MNKD) still slipping today on Pfizer’s insulin scare earlier this month. Pfizer markets an inhaled insulin product, Exubera, that recently studies showed it be connected with lung cancer in its users. Despite the failings of Pfizer’s inhaled insulin product and other developers of similar treatments (including Alkermes above), Mannkind intends to continue developing its similar product, Technosphere. Shares are down almost 7% to $2.33 today on a 52-week range of $2.15 to $15.65. Pfizer (NYSE: PFE) up marginally today to $20.53 on a 52-week range of $20.19 to $27.73.

Generex Biotechnology Corp. (NASDAQ: GNBT) could benefit from Pfizer’s and Mannkind’s struggles with inhaled insulin treatments. Generex’s product Oral-lyn is viewed as a competing oral insulin product that is safe and effective. Shares are up over 2% to $1.18 today on a 52-week range of $0.81 to $2.14.

Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) down almost 11% today after they announced that the pre-clinical study of their anti-PS Vascular Targeting Antibodies showed a broad range of potential for cancer treatment at the American Association of Cancer Research annual meeting. Shares are down to $0.44 on a 52-week range of $0.35 to $1.40.

Rachel Lopez
April 14, 2008

The 52-Week Low Club

247wallst — Mon, 17 Dec 2007 16:08:47 +0000

Bearingpoint (BE) Still dropping after loss earlier in the month. Down to $2.53 from 52-week $8.56.

General Growth Properties (GGP) REIT stocks are getting killed. Falls to $41.93 from 52-week high of $67.43.

Delta Financial (DFC) Files for bankruptcy. Falls to $.07 from $13.60 at 52-week high.

Peregrine Pharmaceuticals (PPHM) Contract with US government halted. Falls to $.35 from 52-week high of $1.40.

Douglas A. McIntyre

The 52-Week Low Club

247wallst — Thu, 15 Nov 2007 16:38:27 +0000

Novastar Finl Inc (NFI) Poor earnings and possible delisting. Drops to $1.72 from 52-week high of $127.20.

Standard Pacific (SPF) Home builder. Down to $3.66 from 52-week high of $30.52.

Fannie Mae (FNM) Bad loans worse than expected. Falls to $32.16 from $70.57.

Home Solutions (HSOA) Delays quarterly filing. Slips to $1.50 from 52-week high $8.24.

Peregrine Pharmaceuticals (PPHM) Problems will clinical trials still pushing shares down. Drops to $.44 from 52-week high of $1.40.

Douglas A. McIntyre

The Nasdaq: Where Delisting Means Nothing

247wallst — Tue, 18 Sep 2007 05:03:13 +0000

Dell (DELL) got another delisting warning yesterday. It has to file its financials on time, or risk being thrown off the exchange. Dell has gotten a number of these. but Nasdaq (NDAQ) keeps pushing the decision off.

Even tiny companies like Peregrine Pharmaceuticals (PPHM) can’t get delisted. The company got a notice on July 15. The firm’s stock trades under $1. But, it has 180 days to get its shares back above that level. And, according to Nasdaq rules "If we (PPHM) are still not in compliance with the minimum closing bid price requirement after the initial 180 calendar day period but we are in compliance with all initial listing requirements other than the bid requirement, we will be afforded an additional "compliance period" of 180 calendar days within which to regain compliance."

If nothing else works, a company can do a reverse merger to get is price above $1.

Of course, Nasdaq does not want to lose any of these companies. They pay listing fees. And, how would it look if the exchange pushed out a big firm like Dell. If it did, it might have to delist all of those other firms that are not obeying the rules.

Nasdaq’s listing requirements are a joke

Douglas A. McIntyre

Blackstone (BX) Leads The 52-Week Low Club

247wallst — Fri, 29 Jun 2007 15:17:50 +0000

Blackstone (BX) Investors still worry about slowing private equity and tax issues. Shares fall to $28.75 from post-IPO high of $38.

American Home Mtg (AHM) Forecasts second quarter loss on delinquent mortagages. Also downgrade by Friedman Billings Ramsey. Drops to $17.40 from 52-week high of $36.40.

Beazer Homes (BZH) More fall-out in home building markets. Drops to $24.02 from 52-week high of $48.50.

Lennar (LEN) Another home builder. Down to $36.37 from 52-week high of $56.54.

Office Depot (ODP) Projects Q2 earnings decline and falling same-store sales. Drops to $30.10 from 52-week high of $44.69.

Circuit City Stores (CC) Continuing concerns about slow sales at electronics firm. Down to $15.04 from 52-week high of $29.31.

Wachovia (WB) One of nation’s largest banks, research firm Punk, Ziegel & Co says that "The poor performance is not due to poor performance by the company. It is due to the poor positioning of the stock by management." Interesting theory. Shares down to $50.84 from 52-week high of $58.80.

Peregrine Pharmaceuticals (PPHM) Company to sell $22.5 million worth of shares. Drops to $.72 from 52-week high of $1.49.

Spreadtrum Communications (SPRD) Chinese designer and marketer of semiconductor for mobile phones just had IPO. Down to $14 from $17.

Panacos Pharmaceuticals (PANC) HIV drug research firms raises $20 million in debt. Shares down to $3.11 from 52-week high of $7.23.

The Finish Line (FINL) Athletic shoe retailer says same-store sales look bad. Drops to $8.98 from 52-week high of $14.97.

Douglas A. McIntyre